CanSense

CanSense develops an early-stage blood test for bowel cancer using laser spectroscopy and artificial intelligence.

Swansea, UK

£1.5MTotal raised

CanSense has developed a blood test combining laser spectroscopy and artificial intelligence to diagnose bowel cancer early. The method offers a faster, less invasive alternative to traditional colonoscopies.

Team

Peter Dunstan

Professor

Peter brings academic and spinout experience as a professor at Swansea University and co-founder of CanSense.

Dean Harris

Professor

Dean brings clinical and academic experience as a colorectal surgeon, professor, and NHS entrepreneur. He serves as a director at CanSense and Swansea University.

Cerys Jenkins

Adam Bryant

CEO

Adam serves as chief executive officer at CanSense. He previously held senior sales roles at Credit Suisse and UBS, alongside an executive chairmanship at London Block Exchange.